한국인 주요우울증 환자에서의 세로토닌 5A 수용체의 유전자 다형성 및 citalopram 치료반응과의 관련성
Association analysis of the 5-HT5A rReceptor gene Gene polymorphisms Polymorphisms and citalopram Citalopram response Response in Korean patients Patients with major Major depressive Depressive disorderDisorder
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The 5-HT5A receptors are expressed exclusively in the brain, mainly in the cerebral cortex, hippocampus. As it is evident that there is a dysfunction of the serotonergic neurotransmitter system in depression, the human 5-HT5A gene is a good candidate gene for susceptibility to depression or in influencing clinical response to antidepressant. Some reports have suggested that 5-HT5A polymorphism allelic association was associated with depression, however, to our knowledge, there has not been studyno report about relationship between the 5-HT5A gene and antidepressant response. We conducted the association study of the 5-HT5A receptor gene polymorphisms(-19G/C,12A/T) and citalopram response in Korean patients with major depressive disorder (MDD). Methods: A total of 106 MDD patients with major depressive disorder were included in this study. The patient’s symptoms were measured by 21-item Hamilton Depression Rating Scale (HAMD) on baseline, week1, week2, week4 and week 8 during citalopram treatment. Responder to citalopram was defined by 50% reduction of total HAMD scores. To analyze genetic polymorphisms, a polymerase chain reaction (PCR) based method was used. Results: At week 8, responders were 62, non-responders were 44. No significant differences of genotypes or allelic association in 19G/C and 12A/T polymorphisms were observed with between responsive and non-responsive patients. Conclusion: These results do not support the hypothesis that this polymorphism of the HT5A receptor gene is involved in the therapeutic response to citalopram.
Abstract
Background: The 5-HT5A receptors are expressed exclusively in the brain, mainly in the cerebral cortex, hippocampus. As it is evident that there is a dysfunction of the serotonergic neurotransmitter system in depression, the human 5-HT5A gene is a good candidate gene for susceptibility to depression or in influencing clinical response to antidepressant. Some reports have suggested that 5-HT5A polymorphism allelic association was associated with depression, however, to our knowledge, there has not been studyno report about relationship between the 5-HT5A gene and antidepressant response. We conducted the association study of the 5-HT5A receptor gene polymorphisms(-19G/C,12A/T) and citalopram response in Korean patients with major depressive disorder (MDD). Methods: A total of 106 MDD patients with major depressive disorder were included in this study. The patient’s symptoms were measured by 21-item Hamilton Depression Rating Scale (HAMD) on baseline, week1, week2, week4 and week 8 during citalopram treatment. Responder to citalopram was defined by 50% reduction of total HAMD scores. To analyze genetic polymorphisms, a polymerase chain reaction (PCR) based method was used. Results: At week 8, responders were 62, non-responders were 44. No significant differences of genotypes or allelic association in 19G/C and 12A/T polymorphisms were observed with between responsive and non-responsive patients. Conclusion: These results do not support the hypothesis that this polymorphism of the HT5A receptor gene is involved in the therapeutic response to citalopram.
참고문헌 (20)
- J. Licinio, "The pharmacogenomics of Depression", Pharmacogenomics J, 1, pp.175~177 (2001)
- Entsuah AR., "Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo", J Clin Psychiatry, 62, pp.869~877 (2001)
- Hyttel J., "Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)", Int Clin Psychopharmacol, 9(1), pp.19~26 (1994)
- Glennon RA., "Serotonin receptor subtypes, Psychopharmacology; The Fourth Generation of Progress", pp.1125~1131 (1995), Raven Press
- Cusin C., "Influence of monoamine oxydase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity", Int J europsychopharmacol, 5, pp.27~35 (2002)
- Minov C., "Serotonin-2A-receptor and -transporter polymorphisms:lack of association in patients with major depression", Neurosci Lett, 303, pp.119~122 (2001)
- Sato K., "Association between -1438G", A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder, 2002, pp.46, 136~140
- Choi MJ, "Association between major depressive disorder and the -1438A", G polymorphism of the serotonin 2A receptor gene, 2004, pp.49, 38~41
- Choi MJ, "Serotonin Receptor 2A Gene Polymorphism (–1438A", G) and Short-Term Treatment Response to Citalopram, 2005, pp.52, 155~162
- Nelson DL., "5HT5A receptors", Curr Drug Targets CNS Neurol Disord, 3(1), pp.53~58 (2004)
- Schanen NC., "Assignment of the 5-hydroxytryptamine (serotonin) receptor 5A gene (HTR5A) to human chromosome band 7q36.1", Cytogenetics and Cell Genetics, 72, pp.187~188 (1996)
- Grailhe R., "Human 5-HT5A receptor;the 5-HT5A receptor is functional but the 5-HT5B receptor was lost during mammalian evolution", Eur J Pharmacol, 418, pp.157~167 (2001)
- Iwata N., "Association of a 5-HT(5A) receptor polymorphism, C43T, to schizophrenia", Molecular Psychiatry, 6, pp.217~219 (2001)
- Birkett JT., "Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response", Neuroreport, 11(9), pp.2017~2020 (2000)
- Arias B., "Genetic variation in the 5-HT5A receptor gene in patients with bipolar disorder and major depression", Neurosci Lett, 303(2), pp.111~114 (2001)
- Dubertret C., "Family-based association studies between 5HT-5A receptor gene and schizophrenia", J of Psychiatric research, 28, pp.371~376 (2004)
- Baumann P., "Pharmacology and pharmacokinetics of citalopram and other SSRIs", Int Clin Psychopharmacol, 11(1), pp.5~11 (1996)
- Han OS., "Structured Clinical Interview for DSM-IV Axis I Disorder -Korean Version" (2000), Hana Medical Publishing Co.,
- Hamilton M, "Development of a rating scale for primary depressive illness", Br J Soc Clin Psychol, 6, pp.278~296 (1967)
- Beck AT., "Erbaugh J. An inventory for measuring depression", Arch Gen Psychiatry, 5, pp.561~571 (1961)